Related Experiment Video
Updated: May 23, 2026

Anti-virulent Disruption of Pathogenic Biofilms using Engineered Quorum-quenching Lactonases
Published on: January 1, 2016
The potential role of quorum-sensing peptides in oncology
E Wynendaele1, E Pauwels, C Van de Wiele
1Drug Quality and Registration (DruQuaR) Group, Faculty of Pharmaceutical Sciences, Ghent University, Harelbekestraat 72, B-9000 Ghent, Belgium.
Abstract:
Cancer is a leading cause of death worldwide, with a limited cure rate and late diagnosis for certain types of cancer (e.g. pancreatic cancer). As this disease presents an enormous challenge for scientists, new paradigms in oncology are needed to defeat this serious disease. Currently, several peptide drugs are investigated for their preventive, diagnostic and therapeutic properties in oncology, with already 15 peptide drugs marketed for cancer therapy. However, we suggest that quorum-sensing peptide agonists and antagonists can be used in oncology as well, resulting in a larger potential peptide space. This hypothesis is based on (1) the recent evidence of prokaryote-eukaryote signalling by the use of quorum-sensing signalling molecules, (2) the apoptotic phenomenon seen in bacteria, (3) the clear similarities between the bacterial quorum-sensing mechanisms and the metastatic process tumor cells initiate, (4) the multiple receptor targeting and (5) the possibility of pharmacologic manipulation of peptides, resulting in increased receptor targeting. Up till now, however, the use of quorum-sensing signalling peptides in oncology has not yet been investigated, despite the urgent need for new insights in oncology and the promising perspectives.
Insights
Quorum-sensing peptides, used in bacteria, show potential for cancer therapy. This novel approach could expand peptide drug development for oncology, offering new treatment avenues.
Area of Science:
- Oncology
- Microbiology
- Drug Discovery
Background:
- Cancer remains a leading global cause of death, necessitating innovative treatment strategies.
- Current oncology research explores peptide drugs, with 15 already approved for cancer therapy.
- Late diagnosis and limited cures for some cancers highlight the need for new therapeutic paradigms.
Purpose of the Study:
- To propose quorum-sensing peptide agonists and antagonists as a novel therapeutic strategy in oncology.
- To explore the potential of quorum-sensing peptides to expand the available peptide drug space for cancer treatment.
Main Methods:
- Reviewing evidence of prokaryote-eukaryote signaling via quorum-sensing molecules.
- Comparing bacterial quorum-sensing mechanisms with tumor cell metastasis.
- Analyzing the potential for multiple receptor targeting and pharmacologic manipulation of peptides.
Main Results:
- The study hypothesizes that quorum-sensing peptides can be leveraged in oncology.
- Identified similarities between bacterial quorum sensing and cancer cell metastasis.
- Highlighted the potential for enhanced receptor targeting through peptide manipulation.
Conclusions:
- Quorum-sensing peptides represent a largely unexplored area in oncology.
- This approach offers a promising avenue for developing novel cancer therapeutics.
- Further investigation into quorum-sensing peptides is warranted for their potential in cancer treatment.
Related Concept Videos
Gene Regulation in Microbial Communities: Quorum Sensing
Bacterial Signaling
Abnormal Proliferation
Mitogens and the Cell Cycle
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

